Buscar

01/10/2024 DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT
Gagelmann, N, De Witte, M, Peczynski, C, Boreland, W, Broers, A, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Byrne, J, Bethge, W, Maertens, J, St lzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kr ger, N, Corradini, P, Finazzi, MC, Corral, L, Villar, S, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. DARATUMUMAB FOR PURE RED CELL APLASIA AFTER HEMATOPOIETIC CELL TRANSPLANTATION: A STUDY FROM THE TRANSPLANT COMPLICATIONS WORKING PARTY OF EBMT. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024 RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY
G mez, VE, Corral, LL, Mahillo, BA, Mellado, PA, Dom nguez, FMM, G mez, MA, Cant , PA, G mez, JM, Ochando, MT, Borrego, AB, Pinedo, LG, Ripa, MTZ, Vicent, MG, Vallejos, AB, Izquierdo, I, Cadenas, IG, Velao, SR, Musseti, A, Giro, EC, Moraleda, PP, Pascual, GO, Sierra, PAG, Garc a, L, Guti rrez, VG, P rez-Sim n, JA. RUXOLITINIB IN ACUTE AND CHRONIC GRAFT-VERSUS-RECEPTOR DISEASE: LONG-TERM REAL-LIFE EXPERIENCE IN A MULTI-CENTRE STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024 FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC)
Salas, MQ, Solano, MT, Baile-Gonz lez, M, Acera-G mez, M, Fox, L, del Mar P rez-Artigas, M, Santamar a, A, Quintela-Gonz lez, MDC, S nchez-Salinas, A, Salmer n-Camacho, JM, Illana-Alvaro, V, Abdallahi-Lefdil, Z, Cornago-Navascues, J, Pardo, L, Fern ndez-Luis, S, Vega-Su rez, LP, Villar, S, Beorlegui-Murillo, P, Esquirol, A, Izquierdo-Garc a, I, Gonz lez, SR, Mussetti, A, Lavilla, E, L pez-Marin, J, Cedillo, A, Bento, L, Sureda, A. FRAILTY ASSESSMENT IN ADULTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION OUTCOMES. PROSPECTIVE STUDY ON BEHALF OF THE GRUPO ESPANOL DE TRASPLANTE HEMATOPOYETICO Y TERAPIA CELULAR (GETH-TC). BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).
01/10/2024 OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY
Fern ndez-Barge, T, Dom nguez-Garcia, JJ, Escamilla, MS, Caballer, JS, Chorao, P, Boluda, JCH, Velao, SR, Cadenas, IG, Bufarull, RM, Estefania, RC, Alexandre, IF, Pe a, AG, Garc a, AT, Ruiz, RG, Luis, SF, San Miguel, EMO, Ara jo, MC, Pell n, SGD, Rodr guez, MAB. OUTCOMES OF ALLOGENEIC HAEMATOPOIETIC STEM-CELL TRANSPLANTATION IN MYELOFIBROSIS: A MULTICENTER STUDY. BONE MARROW TRANSPLANTATION. 2024; 59DOI:. PMID:. IF:5.200(Q1/1D).